<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Porcine factor VIII (pFVIII), which is used to control <z:mp ids='MP_0001914'>bleeding</z:mp> in patients with congenital or <z:e sem="disease" ids="C1096116" disease_type="Disease or Syndrome" abbrv="">acquired haemophilia</z:e> who have high-titre neutralizing antibodies to human FVIII, is not known to increase the risk of arterial or <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We have recently encountered a patient with <z:e sem="disease" ids="C1096116" disease_type="Disease or Syndrome" abbrv="">acquired haemophilia</z:e> who developed a thrombotic left middle cerebral artery distribution <z:hpo ids='HP_0001297'>stroke</z:hpo> while being treated with pFVIII </plain></SENT>
<SENT sid="2" pm="."><plain>To our knowledge, this is the first such reported thrombotic event </plain></SENT>
<SENT sid="3" pm="."><plain>We speculate that platelet activation induced by pFVIII may have contributed to <z:mp ids='MP_0005048'>thrombosis</z:mp> and suggest that pFVIII be used with caution in elderly patients with pre-existing <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> </plain></SENT>
</text></document>